Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 5/20 | 0.44 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.44 |
| ▸ | PDE4A | P27815 | 2/20 | 0.44 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.44 |
| ▸ | CRACR2A | Q9BSW2 | 4/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.39 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.39 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.39 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.39 |
| ▸ | DRD4 | P21917 | 1/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | APLNR | P35414 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16783020 | 0.92 | PDE4B (0.40) | PDE4DPDE4BPDE4APDE4CCHRNB2 | |
| SCHEMBL16782972 | 0.88 | NPY5R (0.41) | CRACR2ADHODHNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL16782959 | 0.87 | PDE4D (0.46) | PDE4DPDE4BPDE4APDE4CALDH1A1 | |
| SCHEMBL16783071 | 0.87 | PDE4D (0.48) | PDE4DPDE4BPDE4APDE4CALDH1A1 | |
| SCHEMBL16783082 | 0.87 | PDE4D (0.46) | PDE4DPDE4BPDE4APDE4CALDH1A1 | |
| SCHEMBL16804984 | 0.87 | PDE4D (0.46) | PDE4DPDE4BPDE4APDE4CALDH1A1 | |
| SCHEMBL16783023 | 0.86 | PDE4D (0.48) | PDE4DPDE4BPDE4APDE4CALDH1A1 | |
| SCHEMBL16783094 | 0.85 | CRACR2A (0.45) | CRACR2ALMNACHRNB2CHRNB4CHRNA3 | |
| SCHEMBL16782955 | 0.85 | PDE4D (0.41) | PDE4DPDE4BPDE4APDE4CALDH1A1 | |
| SCHEMBL16782954 | 0.84 | NPY5R (0.44) | PDE4DPDE4BPDE4APDE4CCRACR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2015090579-A1 | PYRAZOLYL-BASED CARBOXAMIDES IV | Grünenthal GmbH (DE) | 2015-06-25 | — | — | WO | claimed |
| US-20150166505-A1 | PYRIDINYL-SUBSTITUTED PYRAZOLYL CARBOXAMIDES | Grünenthal GmbH (DE) | 2015-06-18 | — | — | US | claimed |
| WO-2015090579-A1 | PYRAZOLYL-BASED CARBOXAMIDES IV | Grünenthal GmbH (DE) | 2015-06-25 | — | — | WO | disclosed |
| WO-2015090579-A1 | PYRAZOLYL-BASED CARBOXAMIDES IV | Grünenthal GmbH (DE) | 2015-06-25 | — | — | WO | disclosed |
| US-20150166505-A1 | PYRIDINYL-SUBSTITUTED PYRAZOLYL CARBOXAMIDES | Grünenthal GmbH (DE) | 2015-06-18 | — | — | US | disclosed |
| US-20150166505-A1 | PYRIDINYL-SUBSTITUTED PYRAZOLYL CARBOXAMIDES | Grünenthal GmbH (DE) | 2015-06-18 | — | — | US | disclosed |
| US-20150166505-A1 | PYRIDINYL-SUBSTITUTED PYRAZOLYL CARBOXAMIDES | Grünenthal GmbH (DE) | 2015-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150166505-A1 | PYRIDINYL-SUBSTITUTED PYRAZOLYL CARBOXAMIDES | AADAC, NLRP3, NOD2 | PDE4D 3462/4885PDE4B 2316/4885PDE4A 2969/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.